OBJECTIVES: The widespread use of complementary therapies alongside biomedical treatment by people with cancer is not supported by evidence from clinical trials. We aimed to use combined qualitative and quantitative data to describe and measure individualised experiences and outcomes. MATERIALS AND METHODS: In three integrative cancer support centres (two breast cancer only) in the UK, consecutive patients completed the individualised outcome questionnaire Measure Yourself Concerns and Wellbeing (MYCaW) before and after treatment. MYCaW collects quantitative data (seven-point scales) and written qualitative data and the qualitative data were analysed using published categories. RESULTS: Seven hundred eighty-two participants, 92% female, mean age 51 years, nominated a wide range of concerns. Psychological and emotional concerns predominated. At follow-up, the mean change (improvement) in scores (n = 588) were: concern 1, 2.06 (95% CI 1.92-2.20); concern 2, 1.74 (95% CI 1.60-1.90); and well-being, 0.64 (95% CI 0.52-0.75). The most common responses to 'what has been the most important aspect for you?' were 'receiving complementary therapies on an individual or group basis' (26.2%); 'support and understanding received from therapists' (17.1%) and 'time spent with other patients at the centres' (16.1%). Positive (61.5%) and negative (38.5%) descriptions of 'other things affecting your health' correlated with larger and smaller improvement in concerns and well-being, respectively. CONCLUSIONS: In a multicentre evaluation, the MYCaW questionnaire provides rich data about patient experience, changes over time and perceptions of what was important to each individual with cancer within that experience. It is unlikely that meaningful evaluations of this complex intervention could be carried out by quantitative methods alone.
OBJECTIVES: The widespread use of complementary therapies alongside biomedical treatment by people with cancer is not supported by evidence from clinical trials. We aimed to use combined qualitative and quantitative data to describe and measure individualised experiences and outcomes. MATERIALS AND METHODS: In three integrative cancer support centres (two breast cancer only) in the UK, consecutive patients completed the individualised outcome questionnaire Measure Yourself Concerns and Wellbeing (MYCaW) before and after treatment. MYCaW collects quantitative data (seven-point scales) and written qualitative data and the qualitative data were analysed using published categories. RESULTS: Seven hundred eighty-two participants, 92% female, mean age 51 years, nominated a wide range of concerns. Psychological and emotional concerns predominated. At follow-up, the mean change (improvement) in scores (n = 588) were: concern 1, 2.06 (95% CI 1.92-2.20); concern 2, 1.74 (95% CI 1.60-1.90); and well-being, 0.64 (95% CI 0.52-0.75). The most common responses to 'what has been the most important aspect for you?' were 'receiving complementary therapies on an individual or group basis' (26.2%); 'support and understanding received from therapists' (17.1%) and 'time spent with other patients at the centres' (16.1%). Positive (61.5%) and negative (38.5%) descriptions of 'other things affecting your health' correlated with larger and smaller improvement in concerns and well-being, respectively. CONCLUSIONS: In a multicentre evaluation, the MYCaW questionnaire provides rich data about patient experience, changes over time and perceptions of what was important to each individual with cancer within that experience. It is unlikely that meaningful evaluations of this complex intervention could be carried out by quantitative methods alone.
Authors: C Paterson; C E Langan; G A McKaig; P M Anderson; G D Maclaine; L B Rose; S J Walker; M J Campbell Journal: Qual Life Res Date: 2000 Impact factor: 4.147
Authors: A Molassiotis; P Fernández-Ortega; D Pud; G Ozden; J A Scott; V Panteli; A Margulies; M Browall; M Magri; S Selvekerova; E Madsen; L Milovics; I Bruyns; G Gudmundsdottir; S Hummerston; A M-A Ahmad; N Platin; N Kearney; E Patiraki Journal: Ann Oncol Date: 2005-02-02 Impact factor: 32.976
Authors: Mary Koithan; Marja Verhoef; Iris R Bell; Margaret White; Andrea Mulkins; Cheryl Ritenbaugh Journal: J Altern Complement Med Date: 2007 Jul-Aug Impact factor: 2.579
Authors: Laura Weeks; Dugald Seely; Cathy DeGrasse; Shailendra Verma; Heather Boon; Marja Verhoef; Dawn Stacey Journal: Support Care Cancer Date: 2013-11-13 Impact factor: 3.603
Authors: Joshua Bauml; Corey J Langer; Tracey Evans; Sheila N Garland; Krupali Desai; Jun J Mao Journal: Support Care Cancer Date: 2014-04-09 Impact factor: 3.603
Authors: Rachel Jolliffe; Nicole Collaco; Helen Seers; Chris Farrell; Michael J Sawkins; Marie J Polley Journal: Support Care Cancer Date: 2018-09-11 Impact factor: 3.603